Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
Type:
Grant
Filed:
April 30, 2021
Date of Patent:
May 30, 2023
Assignee:
KANCERA AB
Inventors:
Håkan Mellstedt, Styrbjörn Byström, Jan Vågberg, Elisabeth Olsson
Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
Abstract: There is provided a compound of formula I, wherein R1, R2, Q1 and are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
Type:
Grant
Filed:
July 9, 2021
Date of Patent:
May 24, 2022
Assignee:
KANCERA AB
Inventors:
Jan Vågberg, Styrbjörn Byström, Elisabeth Olsson, Mattias Jönsson
Abstract: Compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
Type:
Grant
Filed:
July 10, 2017
Date of Patent:
May 18, 2021
Assignee:
KANCERA AB
Inventors:
Håkan Mellstedt, Styrbjörn Byström, Jan Vågberg, Elisabeth Olsson
Abstract: A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in therapy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.
Type:
Grant
Filed:
November 16, 2016
Date of Patent:
May 19, 2020
Assignee:
KANCERA AB
Inventors:
Kristin Hammer, Mattias Jönsson, Lars Krüger
Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
Type:
Grant
Filed:
February 1, 2016
Date of Patent:
February 4, 2020
Assignee:
KANCERA AB
Inventors:
Hakan Mellstedt, Styrbjorn Bystrom, Jan Vagberg, Elisabeth Olsson
Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer.
Type:
Grant
Filed:
May 11, 2015
Date of Patent:
December 24, 2019
Assignee:
KANCERA AB
Inventors:
Johan Schultz, Jan Vågberg, Elisabeth Olsson, Katarina Färnegårdh, Mattias Jönsson, Kristin Hammer, Lars Krüger
Abstract: A compound of formula (I) useful for the treatment of cancer, inflammation and inflammatory disorders, and a pharmaceutical composition containing the compound.
Type:
Grant
Filed:
March 23, 2016
Date of Patent:
June 19, 2018
Assignee:
Kancera AB
Inventors:
Jessica Martinsson, Katarina Faernegardh, Mattias Joensson, Rune Ringom, Nina Gustafsson Sheppard, Thomas Helleday, Petra Groth
Abstract: A compound of formula (I), useful for the treatment of cancer, inflammation and inflammatory disorders, and a pharmaceutical composition containing the compound.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
August 1, 2017
Assignee:
Kancera AB
Inventors:
Jessica Martinsson, Katarina Faernegardh, Mattias Joensson, Rune Ringom
Abstract: The invention relates to antibodies for inducing cell death by the specific binding of (ROR1), domains thereof or nucleotide molecules encoding (ROR1). There are also provided methods involving and uses of the antibodies of the invention.
Abstract: A compound of formula (I), wherein A is S, O or a double bond, and L is a substituted thiazolyl, phenyl or pyridyl. The compound is useful for the treatment of inflammation and cancer.
Type:
Grant
Filed:
September 19, 2011
Date of Patent:
January 12, 2016
Assignee:
KANCERA AB
Inventors:
Styrbjorn Bystrom, Charles Hedgecock, Evert Homan, Thomas Lundback, Jessica Martinsson, Meral Sari, Katarina Farnegardh, Mattias Jonsson
Abstract: The invention relates to antibodies and siRNA molecules for inducing cell death by the specific binding of ROR1, domains thereof of nucleotide molecules encoding ROR1. There are also provided methods involving and uses of the antibodies and siRNA molecules of the invention.
Abstract: A compound of formula (I), wherein A is S, O or a double bond, and L is a substituted thiazolyl, phenyl or pyridyl. The compound is useful for the treatment of inflammation and cancer.
Type:
Application
Filed:
September 19, 2011
Publication date:
July 4, 2013
Applicant:
KANCERA AB
Inventors:
Styrbjorn Bystrom, Charles Hedgecock, Evert Homan, Thomas Lundback, Jessica Martinsson, Meral Sari, Katarina Farnegardh, Mattias Jonsson